<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bsf Enterprise Plc — News on 6ix</title>
<link>https://6ix.com/company/bsf-enterprise-plc</link>
<description>Latest news and press releases for Bsf Enterprise Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 09:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bsf-enterprise-plc" rel="self" type="application/rss+xml" />
<item>
<title>Admission of Shares</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/admission-of-shares-14</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/admission-of-shares-14</guid>
<pubDate>Fri, 17 Apr 2026 09:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has announced the admission of 38,500,000 ordinary shares to the London Stock Exchange, with dealings expected to commence on 21 April 2026 for 4,725,000 previously issued shares from an April 2025 placing. The company also corrected a previous disclosure, stating the correct number of Broker Warrants is 2,310,000, not 23,100. Following these admissions, the total number of ordinary shares and voting rights in the company will be 166,874,437.
Disclaimer*</description>
</item>
<item>
<title>Strategic Shareholding Update</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/strategic-shareholding-update</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/strategic-shareholding-update</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>BSF Enterprise PLC announced that John Story has acquired a significant beneficial interest in the company through a placing, and is expected to become the largest individual shareholder following settlement. Mr. Story, Chairman and principal shareholder of Peers Hardy (UK) Limited, brings extensive experience in retail, branded consumer products, and premium accessories, which the Board believes is highly relevant to BSF's strategy for developing high-value, next-generation materials like its T</description>
</item>
<item>
<title>World’s First T-Rex Leather Handbag Unveiled</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/worlds-first-t-rex-leather-handbag-unveiled</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/worlds-first-t-rex-leather-handbag-unveiled</guid>
<pubDate>Tue, 07 Apr 2026 06:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has unveiled the world's first handbag made from cultivated T-Rex Leather™, a product of its subsidiary Lab-Grown Leather Ltd. This one-of-a-kind luxury item, designed by Enfin Levé, is currently on display at the Art Zoo Museum in Amsterdam until May 10, 2026. The company highlights that this T-Rex Leather™ is not an alternative but a new generation of material, engineered from reconstructed dinosaur collagen using advanced biotechnology, aiming to redefine the material basis</description>
</item>
<item>
<title>Further Investment and Appointment of Adviser</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/further-investment-and-appointment-of-adviser</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/further-investment-and-appointment-of-adviser</guid>
<pubDate>Thu, 02 Apr 2026 14:05:00 GMT</pubDate>
<description>BSF Enterprise PLC has successfully raised £385,000 before expenses through a placing of 38,500,000 new ordinary shares at 1p per share, utilizing its full available headroom and supported by a single strategic investor. The company has also appointed Bowsprit Partners Limited as its Financial Adviser and Broker. In conjunction with the placing, investors will receive 38,500,000 warrants exercisable at 1.5p, and Bowsprit Partners will receive 23,100 warrants exercisable at 1p, both with a three-</description>
</item>
<item>
<title>Supply Agreement with SeaWith</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/supply-agreement-with-seawith</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/supply-agreement-with-seawith</guid>
<pubDate>Thu, 19 Mar 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC's subsidiary, 3D Bio-Tissues Limited, has secured a five-year commercial Supply Agreement with South Korean biotechnology firm SeaWith for its City-Mix® product, valued at approximately £300,000. This agreement will see 3DBT supply City-Mix®, a cell culture enhancer, to support SeaWith's cultivated beef production, potentially reducing SeaWith's growth media costs by 30% and facilitating a phased scale-up of supply volumes through 2030 as SeaWith moves towards large-scale comm</description>
</item>
<item>
<title>LGL Tanning Milestones</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/lgl-tanning-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/lgl-tanning-milestones</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC announced a significant milestone for its subsidiary, Lab-Grown Leather Ltd, successfully tanning scaffold-free, cultivated skin into A4-sized sheets using a new, chromium-free, plant-derived process. This achievement, validated by professional tanners as comparable to traditional leather, represents a critical step towards commercializing sustainable luxury materials and offers a near zero-waste product by eliminating animal rearing and reducing production inefficiencies. The</description>
</item>
<item>
<title>Further Update on Fundraise & Reorganisation</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/further-update-on-fundraise-and-reorganisation</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/further-update-on-fundraise-and-reorganisation</guid>
<pubDate>Fri, 13 Mar 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has mutually terminated its proposed £15 million equity fundraise and capital reorganisation, but a £300,000 convertible loan note will continue on the same terms, extended by 12 months with repayment in cash or conversion rights at the next capital raise price. The company is now actively seeking alternative fundraising options and is in discussions with other parties to secure funds for both the group and its subsidiaries, Lab-grown Leather Ltd and Kerato Ltd, aiming to clos</description>
</item>
<item>
<title>First Tannable A4-Sized Skin Achieved</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/first-tannable-a4-sized-skin-achieved</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/first-tannable-a4-sized-skin-achieved</guid>
<pubDate>Tue, 10 Mar 2026 10:47:00 GMT</pubDate>
<description>BSF Enterprise PLC announced a significant commercial milestone for its subsidiary Lab-Grown Leather Limited, successfully producing a fully tanned, scaffold-free A4-sized skin with a thickness approaching 2mm using its proprietary Advanced Tissue Engineering Platform. This achievement, developed over the last six months, confirms the scalability of the process for its Elemental™ product series, which offers bio-equivalent durability and patina to conventional leather with zero-waste geometry. T</description>
</item>
<item>
<title>Result of Annual General Meeting</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/result-of-annual-general-meeting-182</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/result-of-annual-general-meeting-182</guid>
<pubDate>Tue, 03 Mar 2026 11:00:00 GMT</pubDate>
<description>BSF Enterprise PLC announced that all resolutions were passed by shareholders at its Annual General Meeting. Resolution 1 and 5 received 100% of votes in favour, with 33,470,961 votes. Resolutions 2, 3, 6, and 7 saw 99.99% approval, while Resolution 4 also achieved 99.99% in favour. A small percentage of votes were cast against, and a portion of votes were withheld across various resolutions, with Resolution 4 having the highest number of withheld votes at 12,937,692.
Disclaimer*</description>
</item>
<item>
<title>Update on Proposed Equity Fundraise</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/update-on-proposed-equity-fundraise</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/update-on-proposed-equity-fundraise</guid>
<pubDate>Fri, 27 Feb 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has announced a delay in its proposed equity fundraise and capital reorganisation, which were approved by shareholders on 17 December 2025. The company stated that the process is taking longer than anticipated as it continues to assess options and progress workstreams, and that the equity fundraise remains conditional on the approval of a prospectus. The Board is seeking certainty to ensure timely completion and will provide further updates as appropriate.
Disc</description>
</item>
<item>
<title>Notice of 2026 AGM</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/notice-of-2026-agm-2</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/notice-of-2026-agm-2</guid>
<pubDate>Mon, 09 Feb 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has announced its 2026 Annual General Meeting (AGM) will be held on March 3rd, 2026, at 10 a.m. at Reynolds Porter Chamberlain LLP. The notice of the AGM and the associated proxy form have been distributed to shareholders and submitted to the National Storage Mechanism for inspection. Investors are encouraged to engage with management and share questions via the company's investor website.
Disclaimer*</description>
</item>
<item>
<title>Annual Financial Report - Correction</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/annual-financial-report-correction-2</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/annual-financial-report-correction-2</guid>
<pubDate>Tue, 03 Feb 2026 17:14:00 GMT</pubDate>
<description>BSF Enterprise PLC has issued a correction to its Annual Report and Consolidated Financial Statements for the year ended 30 September 2025, revising the net loss from £1,013,527 to £1,113,527, an increase of £100,000. This adjustment impacts both the RNS Highlights and the Financial Summary on page 6 of the report.
Disclaimer*</description>
</item>
<item>
<title>Annual Financial Report</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/annual-financial-report-477</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/annual-financial-report-477</guid>
<pubDate>Mon, 02 Feb 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has published its Annual Report and Consolidated Financial Statements for the year ended 30 September 2025, detailing significant commercial and technical progress across its subsidiaries. The company reported a reduced net loss of £1,013,527, down from £1,672,291 in the prior year, attributed to cost control and increased grant income. Key developments include the launch of CytoBoost™ and expansion of City-Mix™, a major breakthrough with 2mm-thick scaffold-free leather, and a</description>
</item>
<item>
<title>KERATO LIMITED SIGNS WITH QUEBEC PSO GRANT</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/kerato-limited-signs-with-quebec-pso-grant</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/kerato-limited-signs-with-quebec-pso-grant</guid>
<pubDate>Mon, 19 Jan 2026 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC's subsidiary, Kerato Limited, has secured a CAD 663,000 PSO Grant from the Quebec Ministry of Economy, Innovation and Energy, with Kerato co-funding approximately 55% over 18 months, to advance veterinary trials for its LiQD Cornea product and support North American market entry. This funding will cover safety and biocompatibility testing, veterinary clinical trials at the University of Montreal, and regulatory and intellectual property support, aiming for an initial animal he</description>
</item>
<item>
<title>Result of General Meeting</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/result-of-general-meeting-341</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/result-of-general-meeting-341</guid>
<pubDate>Wed, 17 Dec 2025 11:08:00 GMT</pubDate>
<description>BSF Enterprise PLC announced that all resolutions proposed at its General Meeting were passed by shareholders. Resolution 1 received 36,699,697 votes for and 185,451 against, Resolution 2 received 36,757,931 votes for and 127,217 against, Resolution 3 received 36,745,136 votes for and 140,012 against, Resolution 4 received 36,749,586 votes for and 127,207 against, and Resolution 5 received 36,740,626 votes for and 144,522 against. These strong voting results indicate significant shareholder supp</description>
</item>
<item>
<title>3D Bio-Tissues Signs Supply Agreement with SeaWith</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/3d-bio-tissues-signs-supply-agreement-with-seawith</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/3d-bio-tissues-signs-supply-agreement-with-seawith</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC's subsidiary, 3D Bio-Tissues, has secured a commercial supply agreement with South Korean cultivated-meat company SeaWith, valued at approximately £300,000. This agreement will see 3D Bio-Tissues supply its City-Mix® product to SeaWith, aiming to reduce production costs by around 30% and enhance scalability for SeaWith's cultivated beef. SeaWith, which has raised over $8 million, will utilize City-Mix® to improve cell density and growth efficiency in its production pipeline, m</description>
</item>
<item>
<title>Changes to timetable for proposed Equity Fundraise</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/changes-to-timetable-for-proposed-equity-fundraise</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/changes-to-timetable-for-proposed-equity-fundraise</guid>
<pubDate>Mon, 15 Dec 2025 07:00:00 GMT</pubDate>
<description>BSF Enterprise PLC has updated the timetable for its proposed Equity Fundraise and Capital Reorganisation, with the record date for the Capital Reorganisation now expected around 26 February 2026 and CREST accounts to be credited with new ordinary shares on or around 27 February 2026. The company aims to obtain FCA approval for its prospectus before 28 February 2026, with the Equity Fundraise conditional on this approval and expiring on 26 May 2026. The Directors' unanimous recommendation for sh</description>
</item>
<item>
<title>BSF Enterprise launches new Investor website</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/bsf-enterprise-launches-new-investor-website</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/bsf-enterprise-launches-new-investor-website</guid>
<pubDate>Fri, 05 Dec 2025 09:50:00 GMT</pubDate>
<description>BSF Enterprise PLC has launched a new interactive investor website designed to enhance communication and engagement with both existing and prospective shareholders. This integrated platform consolidates regulatory announcements, reports, presentations, educational materials, interviews, and corporate research, offering a comprehensive resource for stakeholders. The website also features an interactive portal for investors to ask questions and provide feedback, aiming to foster a stronger connect</description>
</item>
<item>
<title>Proposed Equity Fundraise - Strategic Direction</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/proposed-equity-fundraise-strategic-direction</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/proposed-equity-fundraise-strategic-direction</guid>
<pubDate>Mon, 01 Dec 2025 07:02:00 GMT</pubDate>
<description>BSF Enterprise PLC announced a proposed £15 million equity fundraise to accelerate the commercialisation of its tissue-engineered technologies. Approximately £0.5 million will support Kerato's liquid cornea trial, which is partially funded by a Canadian government grant, aiming for veterinary market launch. The funds will also advance 3D Bio-Tissues' CytoBoost REVIVE and other cell culture media supplements, targeting the cryopreservation market. Additionally, BSF plans to allocate proceeds to s</description>
</item>
<item>
<title>Resignation of Chairman</title>
<link>https://6ix.com/company/bsf-enterprise-plc/news/resignation-of-chairman</link>
<guid isPermaLink="true">https://6ix.com/company/bsf-enterprise-plc/news/resignation-of-chairman</guid>
<pubDate>Fri, 29 Aug 2025 09:47:00 GMT</pubDate>
<description>BSF Enterprise PLC announced the resignation of Min Yang from her position as Chairman and Director of the company, effective August 28, 2025. The Board expressed their gratitude for Yang's leadership and contributions during her tenure. The company, which is listed on the LSE under the ticker BSFA, focuses on developing and commercializing tissue-engineered solutions.
Disclaimer*</description>
</item>
</channel>
</rss>